JP2017506623A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506623A5
JP2017506623A5 JP2016549334A JP2016549334A JP2017506623A5 JP 2017506623 A5 JP2017506623 A5 JP 2017506623A5 JP 2016549334 A JP2016549334 A JP 2016549334A JP 2016549334 A JP2016549334 A JP 2016549334A JP 2017506623 A5 JP2017506623 A5 JP 2017506623A5
Authority
JP
Japan
Prior art keywords
bag3
vector
expression
bcl2
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506623A (ja
JP6920818B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/013926 external-priority patent/WO2015117010A2/en
Publication of JP2017506623A publication Critical patent/JP2017506623A/ja
Publication of JP2017506623A5 publication Critical patent/JP2017506623A5/ja
Application granted granted Critical
Publication of JP6920818B2 publication Critical patent/JP6920818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549334A 2014-01-31 2015-01-30 心不全の治療のための標的としてのbag3 Active JP6920818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934483P 2014-01-31 2014-01-31
US61/934,483 2014-01-31
PCT/US2015/013926 WO2015117010A2 (en) 2014-01-31 2015-01-30 Bag3 as a target for therapy of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019191740A Division JP7079761B2 (ja) 2014-01-31 2019-10-21 心不全の治療のための標的としてのbag3

Publications (3)

Publication Number Publication Date
JP2017506623A JP2017506623A (ja) 2017-03-09
JP2017506623A5 true JP2017506623A5 (https=) 2018-05-24
JP6920818B2 JP6920818B2 (ja) 2021-08-18

Family

ID=53757927

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549334A Active JP6920818B2 (ja) 2014-01-31 2015-01-30 心不全の治療のための標的としてのbag3
JP2019191740A Active JP7079761B2 (ja) 2014-01-31 2019-10-21 心不全の治療のための標的としてのbag3
JP2022083707A Active JP7558218B2 (ja) 2014-01-31 2022-05-23 心不全の治療のための標的としてのbag3
JP2024160090A Pending JP2024175055A (ja) 2014-01-31 2024-09-17 心不全の治療のための標的としてのbag3

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019191740A Active JP7079761B2 (ja) 2014-01-31 2019-10-21 心不全の治療のための標的としてのbag3
JP2022083707A Active JP7558218B2 (ja) 2014-01-31 2022-05-23 心不全の治療のための標的としてのbag3
JP2024160090A Pending JP2024175055A (ja) 2014-01-31 2024-09-17 心不全の治療のための標的としてのbag3

Country Status (10)

Country Link
US (3) US11236389B2 (https=)
EP (2) EP3099333B8 (https=)
JP (4) JP6920818B2 (https=)
CA (2) CA3228845A1 (https=)
DK (1) DK3099333T3 (https=)
ES (1) ES2838804T3 (https=)
HU (1) HUE052814T2 (https=)
PT (1) PT3099333T (https=)
SI (1) SI3099333T1 (https=)
WO (1) WO2015117010A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
EP3337518A4 (en) * 2015-08-17 2019-06-12 Temple University Of The Commonwealth System Of Higher Education BAG3 COMPOSITIONS AND METHOD
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
KR101804678B1 (ko) 2016-05-30 2017-12-04 가톨릭대학교 산학협력단 Bis 억제제 스크리닝용 마커, 이를 포함하는 스크리닝 키트 및 이를 이용한 bis 억제제 스크리닝 방법
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
KR20240130829A (ko) * 2016-08-11 2024-08-29 템플 유니버시티 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 허혈/재관류 손상
WO2018129528A1 (en) * 2017-01-09 2018-07-12 Duke University Methods for treating ischemic injury
EP3658582A1 (en) 2017-07-28 2020-06-03 Intrepida Bio, Inc. Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
IT201700113648A1 (it) * 2017-10-10 2019-04-10 Biouniversa Srl Anti-BAG3 antibodies as therapeutic reagent in cardiovascular diseases
SG11202009854XA (en) * 2018-02-15 2020-11-27 Bjoerklund Tomas Modified viral capsids
BR112020025071A2 (pt) * 2018-06-08 2021-03-23 Temple University - Of The Commonwealth System Of Higher Education terapia de otimização de gene bag3
SG11202104756UA (en) 2018-11-08 2021-06-29 Univ Miami Method of determining responsiveness to cell therapy in dilated cardiomyopathy
US20220088127A1 (en) * 2019-01-15 2022-03-24 Temple University - Of The Commonwealth System Of Higher Education Targeting the bag family for the treatment of neurodegenerative disease
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
BR112023006305A2 (pt) 2020-10-09 2023-05-09 Tenaya Therapeutics Inc Métodos e composições de terapia gênica com placofilina-2
AU2022325237A1 (en) * 2021-08-12 2024-03-21 Renovacor, Inc. Retrograde coronary venous or sinus administration of therapeutics
EP4419127A4 (en) * 2021-10-22 2025-11-26 Univ Temple METHODS AND USES OF BAG3 FOR THE TREATMENT OF INFLAMMATION
CA3242351A1 (en) * 2021-12-10 2023-06-15 University Of Florida Research Foundation, Incorporated Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
WO2023147558A2 (en) * 2022-01-28 2023-08-03 Temple University - Of The Commonwealth System Of Higher Education Crispr methods for correcting bag3 gene mutations in vivo
KR20250012749A (ko) * 2022-04-22 2025-01-24 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 b-세포 림프종 2-관련 안타노겐 3(bag3) 유전자 요법
JP2025514489A (ja) * 2022-05-03 2025-05-02 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 脳におけるbag3およびタンパク質品質管理
KR20250075597A (ko) * 2022-09-16 2025-05-28 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 심장 아밀로이드증의 치료를 위한 bag3 방법 및 용도
WO2025255576A1 (en) * 2024-06-07 2025-12-11 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of neurodegeneration

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US4907603A (en) 1988-01-04 1990-03-13 Bertha D. Chambers Safety smoke
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5670113A (en) 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
EP1323733A1 (en) 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
US20030175958A1 (en) * 2002-03-15 2003-09-18 Reed John C. Methods for using bag expression as a cell differentiation agent and marker
WO2009105135A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2012087835A2 (en) * 2010-12-22 2012-06-28 Boston Biomedical Research Institute Compositions and methods for enhancing protein folding
WO2012107580A1 (en) * 2011-02-10 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) In vitro diagnosis method for predicting a predisposition to cardiomyopathy
WO2015117010A2 (en) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
AU2022325237A1 (en) 2021-08-12 2024-03-21 Renovacor, Inc. Retrograde coronary venous or sinus administration of therapeutics

Similar Documents

Publication Publication Date Title
JP2017506623A5 (https=)
DK2299275T3 (en) Classification of oncofetal fetronectin level for pregnancy-related indications
RU2730836C2 (ru) Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
CN109661578B (zh) 用于区分细菌和病毒感染的蛋白质特征
US7659243B2 (en) Treatment of ALS and variants thereof consisting of primary lateral sclerosis (PLS) or spinal muscular atrophy (SMA)
WO2002059604A2 (en) Diagnosis and treatment of multiple sclerosis
JP2022028790A (ja) 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP2013511732A (ja) 神経障害の診断、診断補助および/またはその進行のモニタリングのための方法、キットおよび試薬
CN116322750A (zh) 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法
CN112920275B (zh) 可特异性结合sST2的结合蛋白、试剂和试剂盒
CN115703837B (zh) 一种抗生长刺激表达基因2蛋白的重组抗体
CN114107482A (zh) 肺动脉高压突变基因及其应用
JP2010539891A (ja) 心臓血管及び血栓性の危険性の決定のためのclec1bの使用
JP2009506301A (ja) Pifファミリーの新たなタンパク質アイソフォーム及びその使用
JP2007523640A5 (https=)
TW201643191A (zh) 新穎的igf-1r抗體及其用於癌症診斷之用途(一)
CN104650214B (zh) 肺动脉高压致病基因acvrl1突变位点及其应用
CN112940130A (zh) 能够特异性结合mpo的结合蛋白、其用途、试剂、试剂盒和检测mpo的方法
CN110320367A (zh) 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
EP1259818A2 (en) Diagnosis and treatment of schizophrenia
RU2000119129A (ru) Молекула днк, кодирующая мутантный препронейропептид y, мутантный сигнальный пептид и их применения
TW201643192A (zh) 新穎的igf-1r抗體及其用於癌症診斷之用途(二)
KR102476905B1 (ko) 허혈성 질환 진단 또는 예후 진단용 바이오마커
CN114085900B (zh) 与遗传性肾小球疾病相关的突变基因及其应用
CN114875130B (zh) Lpin3蛋白或编码lpin3蛋白的基因在作为急性肾损伤的生物标志物中的应用